All stock lists
argenx SE (NASDAQ:ARGX)
NL · Delayed Price · Currency is USD
Healthcare · Biotechnology
$964.41-$16.91 (-1.72%)
Market cap
$59.9B
Insider Score
Health Score
Analyst consensus
Listed since
May 18, 2017
Website
Insider Score
––Not scored
ARGX Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
ARGX analyst forecast
ARGX analyst consensus
Moderate Buy14 ratings
Buy 13 Hold 1 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
ARGX 12-month price target
$1,131.40+17.6% upsideaverage of 10 firms
$1,400.00High
$861.00Low
Best analysts covering ARGX
- JP Morgan100%success rate · +27.4% avg return · 7 calls
- Oppenheimer100%success rate · +33.0% avg return · 6 calls
- Evercore ISI Group100%success rate · +39.8% avg return · 4 calls
- B of A Securities100%success rate · +39.2% avg return · 2 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
ARGX analyst ratings
Filters
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | Citigroup | Buy | — | — | Reiterated | 2026-10-27 |
| Morgan Stanley | Overweight | $1,190.00 | +35.9% | Reiterated | 2026-10-23 | |
| — | Evercore ISI Group | Outperform | — | — | Reiterated | 2026-10-23 |
| Wells Fargo | Overweight | $1,355.00 | +65.5% | Reiterated | 2026-10-23 | |
| Guggenheim | Buy | $1,135.00 | +44.2% | Reiterated | 2026-10-23 | |
| — | Baird | Neutral | — | — | Reiterated | 2026-10-23 |
| Robert W. Baird | — | $861.00 | -1.7% | Price target | 2026-10-23 | |
| Stifel Nicolaus | — | $1,200.00 | +35.4% | Price target | 2026-10-22 | |
| RBC Capital | Outperform | $1,100.00 | +11.4% | Reiterated | 2026-10-20 | |
| Oppenheimer | Outperform | $1,038.00 | +26.2% | Reiterated | 2026-10-12 | |
| Robert W. Baird | — | $823.00 | +0.5% | Price target | 2026-10-09 | |
| Stifel Nicolaus | — | $1,282.00 | +61.1% | Price target | 2026-10-08 | |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-09-08 |
| Morgan Stanley | Overweight | $1,180.00 | +35.7% | Reiterated | 2026-08-31 | |
| Wells Fargo | Overweight | $1,415.00 | +38.8% | Reiterated | 2026-08-26 | |
| UBS | Buy | $1,400.00 | +37.3% | Upgraded | 2026-08-26 | |
| HC Wainwright & Co. | Buy | $940.00 | +15.6% | Reiterated | 2026-08-18 | |
| — | Citizens | Market Outperform | — | — | Reiterated | 2026-08-18 |
| Truist Securities | Buy | $1,095.00 | +10.8% | Reiterated | 2026-08-18 | |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2026-08-17 |
| RBC Capital | Outperform | $890.00 | +4.0% | Reiterated | 2026-07-24 | |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2026-07-24 |
| — | B of A Securities | Buy | — | — | Reiterated | 2026-07-02 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-06-01 |
| Stifel Nicolaus | — | $1,255.00 | +49.7% | Price target | 2026-05-28 | |
| Morgan Stanley | Overweight | $1,170.00 | +48.3% | Price target | 2026-05-08 | |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-02-27 |
| Guggenheim | Buy | $1,160.00 | +36.4% | Reiterated | 2026-02-27 | |
| RBC Capital | Outperform | $850.00 | +25.5% | Reiterated | 2026-02-27 | |
| Stifel Nicolaus | — | $1,227.00 | +59.4% | Price target | 2026-02-26 | |
| Truist Securities | Buy | $1,030.00 | +25.2% | Reiterated | 2026-01-08 | |
| Morgan Stanley | Overweight | $1,160.00 | +41.0% | Price target | 2026-01-08 | |
| — | Baird | Neutral | — | — | Downgraded | 2025-12-18 |
| Robert W. Baird | — | $858.00 | -0.5% | Price target | 2025-12-18 | |
| — | Stifel | Buy | — | — | Reiterated | 2025-12-11 |
| UBS | — | $910.00 | +1.0% | Price target | 2025-12-09 | |
| — | JP Morgan | Overweight | — | — | Reiterated | 2025-12-08 |
| Morgan Stanley | Overweight | $1,110.00 | +20.6% | Reiterated | 2025-12-04 | |
| — | Wolfe Research | Peer Perform | — | — | Downgraded | 2025-11-24 |
ARGX earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2025-05-08 | $2.32 | $2.58 | $861.8M | $573.2M |
| 2025-10-30 | $4.37 | $5.18 | $1.28B | $948.0M |
| 2026-05-07 | $5.16 | $5.90 | $1.45B | $3.21B |
| 2026-07-30 | $7.44 | $7.80 | $1.66B | $2.82B |
| 2027-02-25Upcoming | $7.57 | — | $3.35B | — |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.